VHL mediates tumour invasion and metastasis by regulating HIF protein expression, and VHL mutations predispose patients to several angiogenic tumours (familiar VHL tumour syndrome) and familial erythrocytosis 2 (ECYT2) [2, 3]. This evidence concerns the gene VHL and primary familial polycythemia due to EPO receptor mutation.